Oganov R G, Mustafaev I I, Perova N V, Postol'nikov S F, Metel'skaia V A
Kardiologiia. 1985 Aug;25(8):17-22.
A comparative study of changes in plasma lipids, apo-A1 and apo-B under the effect of 2-week, 2-month and 6-month treatments with hydrochlorothiazide and pratsiol was conducted in 48 patients with arterial hypertension. Hydrochlorothiazide caused a significant increase in total cholesterol (CH), LDL cholesterol, apo-A1 and apo-B, and a decrease in cholesterol load of HDL particles as compared to placebo effects. Increased levels of HDL cholesterol were only noted in the early days of hydrochlorothiazide treatment. Pratsiol therapy produced a significant reduction of total triglycerides (TG), VLDL cholesterol, the cholesterol atherogenic coefficient, the apo-B/apo-A1 ratio, and increased HDL cholesterol. The activity of post-heparin lipoprotein lipase was not basically affected by hydrochlorothiazide, while pratsiol evoked a significant increase in its activity. The pratsiol-associated TG decrease was more pronounced in patients with elevated TG baseline, and the rise in HDL cholesterol, in those with initial hypo-alphacholesterolemia. Therefore unlike hydrochlorothiazide, pratsiol is associated with a favorable antiatherogenic trend of changes in the lipoprotein spectrum.
对48例动脉高血压患者进行了一项对比研究，观察氢氯噻嗪和普拉西奥分别治疗2周、2个月和6个月对血脂、载脂蛋白A1（apo-A1）和载脂蛋白B（apo-B）的影响。与安慰剂效应相比，氢氯噻嗪导致总胆固醇（CH）、低密度脂蛋白胆固醇、apo-A1和apo-B显著升高，高密度脂蛋白颗粒的胆固醇负荷降低。仅在氢氯噻嗪治疗早期观察到高密度脂蛋白胆固醇水平升高。普拉西奥治疗使总甘油三酯（TG）、极低密度脂蛋白胆固醇、胆固醇致动脉粥样硬化系数、apo-B/apo-A1比值显著降低，并使高密度脂蛋白胆固醇升高。肝素后脂蛋白脂肪酶的活性基本不受氢氯噻嗪影响，而普拉西奥使其活性显著增加。普拉西奥相关的甘油三酯降低在基线甘油三酯升高的患者中更为明显，而高密度脂蛋白胆固醇升高在初始低α胆固醇血症患者中更为明显。因此，与氢氯噻嗪不同，普拉西奥与脂蛋白谱变化的有利抗动脉粥样硬化趋势相关。
